
|Videos|January 16, 2015
Predictive Value of Diagnostic Tests
Advertisement
Bryan Loy, MD, describes how diagnostic test results can be of help to providers when having conversations with their patients about treatments. Providing patients with a more specific concept of response and recurrence, such as percentages or odds, can help patients understand their options.
Advertisement
Related to this article

The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5





